Knut E.A. Lundin

Author information from the last article

Knut E.A. Lundin (born 1958) is an associate professor and senior consultant at Oslo University Hospital.

The author has completed the ICMJE form and declares the following conflicts of interest: He has received fees from Abbvie, MSD, OrionPharma, Hospira, TakedaNycomed, Meda, Regeneron and GlaxoSmithKline.

Articles by Knut E.A. Lundin

A system for students' evaluation of lectures in the medical programme in Oslo

Sunneva Stokke,
Ingeborg L. Solberg,
Per Grøttum,
Knut E.A. Lundin,
Kristin M. Heggen,
Jarle Breivik

15.08.2019: Education authorities, students and employers are placing increasing demands on quality in higher education. A large emphasis is also being placed on students taking an active role in the development of the teaching (1). Student surveys suggest that medical studies in Norway are not fulfilling this...

Electives in the medical degree programme

Jan C. Frich,
Jarle Breivik,
Knut E.A. Lundin,
Elin O. Rosvold,
Ingrid Os

30.10.2017: As a part of a major review of the medical degree programme in Oslo, elective courses were introduced for the first time in the spring term of 2017. We believe this will give opportunities for in-depth study and provide useful experience with a view to future career choices. It is common practice in...

Biosimilar medicines in inflammatory bowel disease

Bjørn Moum,
Knut E.A. Lundin

29.04.2014: Treatment of ulcerative colitis and Crohn’s disease with biological medicines is usually effective, but costly. The patent on the first medicine to come on the market has expired, and a much cheaper biosimilar medicine has recently been registered. The new medicine is now recommended as the first...